284 related articles for article (PubMed ID: 33759204)
1. Scientific considerations to move towards biowaiver for biopharmaceutical classification system class III drugs: How modeling and simulation can help.
Wu F; Cristofoletti R; Zhao L; Rostami-Hodjegan A
Biopharm Drug Dispos; 2021 Apr; 42(4):118-127. PubMed ID: 33759204
[TBL] [Abstract][Full Text] [Related]
2. Feasibility of biowaiver extension to biopharmaceutics classification system class III drug products: cimetidine.
Jantratid E; Prakongpan S; Amidon GL; Dressman JB
Clin Pharmacokinet; 2006; 45(4):385-99. PubMed ID: 16584285
[TBL] [Abstract][Full Text] [Related]
3. The Biopharmaceutics Classification System: subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC.
Tsume Y; Mudie DM; Langguth P; Amidon GE; Amidon GL
Eur J Pharm Sci; 2014 Jun; 57():152-63. PubMed ID: 24486482
[TBL] [Abstract][Full Text] [Related]
4. Classification of torasemide based on the Biopharmaceutics Classification System and evaluation of the FDA biowaiver provision for generic products of CLASS I drugs.
Khan MZ; Rausl D; Radosević S; Filić D; Danilovski A; Dumić M; Knezević Z
J Pharm Pharmacol; 2006 Nov; 58(11):1475-82. PubMed ID: 17132210
[TBL] [Abstract][Full Text] [Related]
5. Effect of the Similarity of Formulations and Excipients of Approved Generic Drug Products on In Vivo Bioequivalence for Putative Biopharmaceutics Classification System Class III Drugs.
Ren P; Chan T; Yang WC; Frost M; Wang Y; Luke M; Kim MJ; Lionberger R; Zhang Y
Pharmaceutics; 2023 Sep; 15(9):. PubMed ID: 37765334
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic simulation of biowaiver criteria: the effects of gastric emptying, dissolution, absorption and elimination rates.
Kortejärvi H; Urtti A; Yliperttula M
Eur J Pharm Sci; 2007 Feb; 30(2):155-66. PubMed ID: 17187967
[TBL] [Abstract][Full Text] [Related]
7. Very rapid dissolution is not needed to guarantee bioequivalence for biopharmaceutics classification system (BCS) I drugs.
Kortejärvi H; Shawahna R; Koski A; Malkki J; Ojala K; Yliperttula M
J Pharm Sci; 2010 Feb; 99(2):621-5. PubMed ID: 19844950
[TBL] [Abstract][Full Text] [Related]
8. Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Metformin Hydrochloride.
Metry M; Shu Y; Abrahamsson B; Cristofoletti R; Dressman JB; Groot DW; Parr A; Langguth P; Shah VP; Tajiri T; Mehta MU; Polli JE
J Pharm Sci; 2021 Apr; 110(4):1513-1526. PubMed ID: 33450218
[TBL] [Abstract][Full Text] [Related]
9. Biowaiver Monograph for Immediate-Release Dosage Forms: Levamisole Hydrochloride.
Kambayashi A; de Meijer M; Wegman K; van Veldhuizen C; Abrahamsson B; Cristofoletti R; Langguth P; Mehta M; Parr A; Polli JE; Shah VP; Dressman J
J Pharm Sci; 2023 Mar; 112(3):634-639. PubMed ID: 36563854
[TBL] [Abstract][Full Text] [Related]
10. Biowaiver monograph for immediate-release solid oral dosage forms: fluconazole.
Charoo N; Cristofoletti R; Graham A; Lartey P; Abrahamsson B; Groot DW; Kopp S; Langguth P; Polli J; Shah VP; Dressman J
J Pharm Sci; 2014 Dec; 103(12):3843-3858. PubMed ID: 25312492
[TBL] [Abstract][Full Text] [Related]
11. In silico prediction of drug dissolution and absorption with variation in intestinal pH for BCS class II weak acid drugs: ibuprofen and ketoprofen.
Tsume Y; Langguth P; Garcia-Arieta A; Amidon GL
Biopharm Drug Dispos; 2012 Oct; 33(7):366-77. PubMed ID: 22815122
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Excipient Risk in BCS Class I and III Biowaivers.
Metry M; Polli JE
AAPS J; 2022 Jan; 24(1):20. PubMed ID: 34988701
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Differences in Dosage Form Performance of Generics Using BCS-Based Biowaiver Specifications and Biopharmaceutical Modeling-Case Examples Amoxicillin and Doxycycline.
Hofsäss MA; Dressman J
J Pharm Sci; 2020 Aug; 109(8):2437-2453. PubMed ID: 32339527
[TBL] [Abstract][Full Text] [Related]
14. Possibility of extending biopharmaceutics classification system based biowaiver to BCS class IIa drug.
Khalid F; Hassan SMF; Noor R; Zaheer K; Hassan F
Pak J Pharm Sci; 2019 Sep; 32(5):2065-2073. PubMed ID: 31813872
[TBL] [Abstract][Full Text] [Related]
15. A comparative analysis of biopharmaceutics classification system and biopharmaceutics drug disposition classification system: a cross-sectional survey with 500 bioequivalence studies.
Cristofoletti R; Chiann C; Dressman JB; Storpirtis S
J Pharm Sci; 2013 Sep; 102(9):3136-44. PubMed ID: 23580377
[TBL] [Abstract][Full Text] [Related]
16. Bioequivalence Dissolution Test Criteria for Formulation Development of High Solubility-Low Permeability Drugs.
Ono A; Kurihara R; Terada K; Sugano K
Chem Pharm Bull (Tokyo); 2023; 71(3):213-219. PubMed ID: 36858526
[TBL] [Abstract][Full Text] [Related]
17. BCS Biowaivers: Similarities and Differences Among EMA, FDA, and WHO Requirements.
Davit BM; Kanfer I; Tsang YC; Cardot JM
AAPS J; 2016 May; 18(3):612-8. PubMed ID: 26943914
[TBL] [Abstract][Full Text] [Related]
18. Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Isavuconazonium Sulfate.
Plano D; Rudolph N; Saal C; Abrahamsson B; Cristofoletti R; Kambayashi A; Langguth P; Mehta M; Parr A; Polli JE; Shah VP; Charoo N; Dressman J
J Pharm Sci; 2024 Feb; 113(2):386-395. PubMed ID: 37951471
[TBL] [Abstract][Full Text] [Related]
19. Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Levetiracetam.
Petruševska M; Berglez S; Krisch I; Legen I; Megušar K; Peternel L; Abrahamsson B; Cristofoletti R; Groot DW; Kopp S; Langguth P; Mehta M; Polli JE; Shah VP; Dressman J
J Pharm Sci; 2015 Sep; 104(9):2676-87. PubMed ID: 25663270
[TBL] [Abstract][Full Text] [Related]
20. Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Amoxicillin Trihydrate.
Thambavita D; Galappatthy P; Mannapperuma U; Jayakody L; Cristofoletti R; Abrahamsson B; Groot DW; Langguth P; Mehta M; Parr A; Polli JE; Shah VP; Dressman J
J Pharm Sci; 2017 Oct; 106(10):2930-2945. PubMed ID: 28483422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
